A Retrospective Chart Review of MabThera (Rituximab) Treatment in Rheumatoid Arthritis (RA) Participants in Australia

Roche

Status: Completed

Conditions: Rheumatoid Arthritis

Study type: Observational

Funder types: Industry; Other

Identifiers

NCT02564770

ML28321

Details and patient eligibility

About

This is a cross-sectional, observational study examining the factors leading to the therapeutic decision to use MabThera (rituximab) in participants with RA. Routine rheumatology clinical practice data of participants who are being or have been treated with rituximab for RA will be collected and analysed in this chart review.

Enrollment: 167 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Greater than or equal to (>=) 18 years of age at the time of data collection
• RA diagnosed by a rheumatologist
• Treatment with rituximab for RA

Exclusion criteria

• Participants whose primary diagnosis and indication for rituximab treatment is a condition other than RA
• Participants who have been treated with an experimental agent for RA which is not currently approved for the treatment of RA in Australia

Trial design

167 participants in 1 patient group

Rheumatoid arthritis (RA) participants

Description:

Participants who had been treated with rituximab for RA are reviewed retrospectively using chart review from Baseline until and their most recent visit to the rheumatologist prior to the conduct of the chart review.